Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Northeast Pharmaceutical (000597) had a net sell of 5.8664 million yuan by main funds on March 30.
According to Securities Star, as of the market close on March 30, 2026, Northeast Pharmaceutical (000597) closed at 5.31 yuan, up 1.72%, with a turnover rate of 1.43%, a trading volume of 202,100 lots, and a transaction amount of 107 million yuan.
On March 30, the capital flow data showed that net outflow of major funds amounted to 5.8664 million yuan, accounting for 5.49% of the total transaction amount; net outflow of speculative funds was 7.1458 million yuan, accounting for 6.69% of the total transaction amount; and net inflow of retail funds was 13.0122 million yuan, accounting for 12.18% of the total transaction amount.
Northeast Pharmaceutical’s 2025 Q3 report indicates that for the first three quarters, the company’s main revenue was 5.478 billion yuan, a year-on-year decrease of 10.69%; net profit attributable to the parent company was 173 million yuan, a year-on-year decrease of 16.96%; net profit excluding non-recurring items was 132 million yuan, a year-on-year decrease of 4.32%; of which in Q3 2025, the company’s single-quarter main revenue was 1.625 billion yuan, a year-on-year decrease of 17.28%; single-quarter net profit attributable to the parent company was 43.5245 million yuan, a year-on-year decrease of 14.92%; single-quarter net profit excluding non-recurring items was 42.7891 million yuan, a year-on-year increase of 27.54%; the debt ratio was 58.99%, investment income was 8.4143 million yuan, financial expenses were 9.0214 million yuan, and gross profit margin was 35.03%. Northeast Pharmaceutical (000597) has its main business covering sectors such as chemical pharmaceuticals (raw materials, formulations), pharmaceutical commerce (wholesale, chains), pharmaceutical engineering (pharmaceutical design, manufacturing installation), and biopharmaceuticals (biological diagnostic reagents).
Capital flow explanation: It refers to inferring capital flow through price changes. When stock prices are rising, the transaction amount generated by active buy orders is the force driving the stock price up, and this transaction amount is defined as capital inflow. When stock prices are falling, the transaction amount generated by active sell orders is the force driving the stock price down, and this transaction amount is defined as capital outflow. The difference between the two on that day is the net force remaining after the two forces offset each other, pushing the stock price up. The capital flow of major funds, speculative funds, and retail funds is calculated based on the transaction amount of each individual trade.
Note: Major funds refer to large transactions, speculative funds refer to bigger transactions, and retail funds refer to medium and small transactions.
The above content is compiled by Securities Star based on public information and generated by AI algorithms (Internet Information Office record number 310104345710301240019), and does not constitute investment advice.